Antengene Shows Impressive Progress: TORCH-2 Study Results Revealed at ASCO 2023 for its Advanced Solid Tumor Treatment, ATG-008.

Antengene Corporation Limited (SEHK: 6996.HK), a pioneering global biopharmaceutical company, is thrilled to announce that the newest findings from its Phase I/II TORCH-2 study have been selected for a prestigious presentation slot at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Representing the 22 China studies chosen for Poster Discussions at ASCO 2023, the abstract will be discussed on June 3rd alongside the groundbreaking advances in oncology from around the world.

Dr. Amily Zhang, Antengene’s Chief Medical Officer, is delighted to announce that the latest findings from the TORCH-2 study have been selected for Poster Discussion at ASCO 2023. Antengene looks forward to maintaining a close working relationship with the TORCH-2 investigator team and liaising with regulatory authorities in China and other APAC markets to pursue a registration path in cervical cancer and further explore the combination in further solid tumor studies.

ATG-008 (onatasertib) is an orally available mTORC 1/2 inhibitor. ATG-008 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, has an important role in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.

ATG-008 has been studied in clinical trials to treat a broad range of tumor types including multiple myeloma (MM), glioblastoma (GBM), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), diffuse large B-cell lymphoma (DLBCL), etc.

About ATG-008

ATG-008 (onatasertib) is a promising oral mTORC 1/2 inhibitor that has been investigated in clinical trials to treat a variety of malignancies such as MM, GBM, HCC, NSCLC, DLBCL, etc. It works by inhibiting mTOR activity, which is often deregulated in cancer, leading to the induction of tumor cell apoptosis and decreased tumor cell proliferation. By targeting this crucial signaling pathway, ATG-008 could offer a much-needed therapeutic option for many cancer patients.

About Antengene

Antengene Corporation Limited (SEHK: 6996.HK) is a revolutionary biopharmaceutical company striving to revolutionize the way people treat cancer. With the mission to provide accessible, groundbreaking treatments to everyone, regardless of their location, Antengene provides first-in-class/best-in-class therapies for hematologic malignancies and solid tumors. Through its relentless dedication and passion, Antengene is determined to deliver long-term solutions that will help patients live more fulfilling lives.

Since 2017, Antengene has established an impressive pipeline of nine oncology assets ranging from clinical to commercial stages, with six having global rights and three being exclusive in the Asia-Pacific region. Antengene’s prowess in oncology has been widely recognised, with their investigative new drug (IND) filing having been granted approval in the United States and Asia.

On top of that, their new drug applications (NDAs) have successfully been submitted in multiple regions, with XPOVIO® (selinexor) already approved in China, Taiwan, South Korea, Singapore and Australia.

Leave a Comment